Literature DB >> 10834311

Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies.

D Ito1, K Ogasawara, K Matsushita, T Morohashi, K Namba, N Matsuki, N Kitaichi, Y Inuyama, M Hosokawa, E Nakayama, K Iwabuchi, K Onoé.   

Abstract

Recently it has been shown that modulation of CD40 molecules on antigen (Ag) carrying dendritic cells (DC) can bypass T cell help, resulting in priming cytotoxic T lymphocytes (CTL) specific for the Ag. In the present study we attempted to prime peptide Ag-specific CTL by a new method in which a peptide Ag in liposome (liposomal peptide), consisting of phosphatidylserine and phosphatidylcholine (3:7), was administrated subcutaneously with anti-CD40 and/or CTLA-4 monoclonal antibodies (mAb) to mice. We found that the subcutaneous administration of the liposomal peptide with both anti-CD40 and anti-CTLA-4 mAb enhanced CTL responses comparing with those induced by the liposomal peptide alone or the liposomal peptide plus each mAb. It was shown that liposomes were critical for induction of the CTL activity. Flow cytometry analysis of a peptide-bearing DC in lymph nodes (LN) and measurement of serum IL-12 indicated that anti-CD40 mAb promoted migration of DC to the LN, where DC might differentiate and acquire ability of priming CTL. These findings provide a possibility that our procedure is applicable to cancer patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10834311     DOI: 10.1016/S0171-2985(00)80072-8

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  3 in total

1.  A potent adjuvant effect of CD40 antibody attached to antigen.

Authors:  Tom A Barr; Adele L McCormick; Jennifer Carlring; Andrew W Heath
Journal:  Immunology       Date:  2003-05       Impact factor: 7.397

Review 2.  Therapeutic cancer vaccine: building the future from lessons of the past.

Authors:  T Tran; C Blanc; C Granier; A Saldmann; C Tanchot; Eric Tartour
Journal:  Semin Immunopathol       Date:  2018-07-05       Impact factor: 9.623

Review 3.  Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.

Authors:  Soumaya Karaki; Marie Anson; Thi Tran; Delphine Giusti; Charlotte Blanc; Stephane Oudard; Eric Tartour
Journal:  Vaccines (Basel)       Date:  2016-11-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.